Key facts
- This page summarizes Christopher Mutz's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Mar 2023, 17:48.
Christopher Mutz - 07 Mar 2023 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)
- Reporting relationship
- HEAD OF RARE DISEASE
- Issuer ticker
- ANIP
- Reported as of
- 07 Mar 2023
- Net transaction value
- -$84,125
- SEC form
- 4
- Accepted by SEC
- 09 Mar 2023, 17:48:05 UTC
- Prior SEC filing
- 04 Apr 2023
- Next SEC filing
- 13 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Mutz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Mutz filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 09 Mar 2023.
Change
- Previous filing in this sequence was filed on 04 Apr 2023.
- Current net transaction value: -$84,125.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANIP
transaction
Common Stock
Tax liability
- Transaction value
- $63,072
- Shares
- -1,426
- Change %
- -3.6%
- Price
- $44.23
- Shares after
- 38,136
- Date
- 07 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
ANIP
transaction
Common Stock
Tax liability
- Transaction value
- $21,053
- Shares
- -476
- Change %
- -1.2%
- Price
- $44.23
- Shares after
- 37,660
- Date
- 07 Mar 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,857 shares of restricted stock, the grant of which was previously reported.
Footnote F2
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,619 shares of restricted stock, the grant of which was previously reported.